Cargando…

A Systematic Review Characterizing Psoriatic Arthritis Onset and Exacerbation in Patients Receiving Biologic Therapy

BACKGROUND: While biologic therapies revolutionized treatment of immune-mediated inflammatory diseases (IMIDs), some adverse effects have been noted. This includes the development and exacerbation of PsA in patients on biologic agents, however the outcomes were not extensively explored. OBJECTIVE: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sachdeva, Muskaan, Abduelmula, Abrahim, Mufti, Asfandyar, Georgakopoulos, Jorge R., Lytvyn, Yuliya, Yeung, Jensen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9361424/ https://www.ncbi.nlm.nih.gov/pubmed/35317662 http://dx.doi.org/10.1177/12034754221088556

Ejemplares similares

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Treatment outcomes in patients with papuloerythroderma of Ofuji: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2021)

A systematic review of vitiligo onset and exacerbation in patients receiving biologic therapy
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Drugs Associated With the Development of Palmoplantar Keratoderma: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment
por: Sachdeva, Muskaan, et al.
Publicado: (2020)

Management of vitiligo with topical janus tyrosine kinase inhibitor therapy: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Management of Alopecia Areata With Topical JAK Inhibitor Therapy: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Clinical manifestations and treatment outcomes in prurigo pigmentosa (Nagashima disease): A systematic review of the literature
por: Mufti, Asfandyar, et al.
Publicado: (2021)

34223 Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: A multicenter retrospective cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study
por: Georgakopoulos, Jorge R., et al.
Publicado: (2020)

Reply to: “Skin damage among health care workers managing coronavirus disease 2019”
por: Maliyar, Khalad, et al.
Publicado: (2020)

Biologic treatment outcomes in refractory bullous pemphigoid: An evidence-based review
por: Abduelmula, Abrahim, et al.
Publicado: (2022)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

The Use of Janus Kinase Inhibitors for Lichen Planus: An Evidence-Based Review
por: Abduelmula, Abrahim, et al.
Publicado: (2023)

Eruptive Seborrheic Keratoses Are Associated With a Co-Occurring Malignancy in the Majority of Reported Cases: A Systematic Review
por: Mirali, Sara, et al.
Publicado: (2021)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
por: Lytvyn, Yuliya, et al.
Publicado: (2021)

Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review
por: Sachdeva, Muskaan, et al.
Publicado: (2021)

Treatment outcomes of biologics and small molecules for chronic hand eczema: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)

Modifications to dermatology residency education during the COVID-19 pandemic
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Hereditary haemorrhagic telangiectasia: A case report
por: Mufti, Asfandyar, et al.
Publicado: (2021)

COVID-19 and wound care: A Canadian perspective
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Squamous cell carcinoma arising within discoid lupus erythematous lesions: A systematic review
por: Mufti, Asfandyar, et al.
Publicado: (2020)

Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus ≥0.5-mg/kg/d dosing in acne patients: A systematic review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Biologic therapy for refractory pemphigoid gestationis: An evidence-based systematic review
por: Sood, Siddhartha, et al.
Publicado: (2023)

32414 Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: A multicentre retrospective cohort study
por: Rankin, Brian D., et al.
Publicado: (2022)

New-Onset Psoriatic Arthritis under Biologics in Psoriasis Patients: An Increasing Challenge?
por: Megna, Matteo, et al.
Publicado: (2021)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
por: Bagit, Ahmed, et al.
Publicado: (2023)

Altered Bone Biology in Psoriatic Arthritis
por: Rahimi, Homaira, et al.
Publicado: (2012)

An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis
por: Chimenti, Maria Sole, et al.
Publicado: (2020)

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis
por: Valenzuela, Fernando, et al.
Publicado: (2021)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
por: Cantini, Fabrizio, et al.
Publicado: (2017)

Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting
por: de Camargo, Mayara Costa, et al.
Publicado: (2019)

Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis
por: Kavanaugh, Arthur, et al.
Publicado: (2018)

Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics
por: Silvy, Florent, et al.
Publicado: (2015)

Quo vadis, biological treatment for psoriasis and psoriatic arthritis?
por: Olszewska, Barbara, et al.
Publicado: (2018)

Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis
por: Thibodeaux, Quinn, et al.
Publicado: (2019)

Treatment persistence of biologics among patients with psoriatic arthritis
por: Haddad, Amir, et al.
Publicado: (2021)

Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis
por: Zhang, Hanzhe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j6ob0t5019j69s1v4gt92ntg7m